Cargando…

Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans

INTRODUCTION: In the absence of clinical efficacy data, vaccine protective effect can be extrapolated from animals to humans, using an immunological biomarker in humans that correlates with protection in animals, in a statistical approach called immunobridging. Such an immunobridging approach was pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	McLean, Chelsea, Dijkman, Karin, Gaddah, Auguste, Keshinro, Babajide, Katwere, Michael, Douoguih, Macaya, Robinson, Cynthia, Solforosi, Laura, Czapska-Casey, Dominika, Dekking, Liesbeth, Wollmann, Yvonne, Volkmann, Ariane, Pau, Maria Grazia, Callendret, Benoit, Sadoff, Jerry, Schuitemaker, Hanneke, Zahn, Roland, Luhn, Kerstin, Hendriks, Jenny, Roozendaal, Ramon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505757/ https://www.ncbi.nlm.nih.gov/pubmed/37727795 http://dx.doi.org/10.3389/fimmu.2023.1215302

Ejemplares similares

Protection against Marburg Virus and Sudan Virus in NHP by an Adenovector-Based Trivalent Vaccine Regimen Is Correlated to Humoral Immune Response Levels
por: Tiemessen, Machteld M., et al.
Publicado: (2022)

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
por: Roozendaal, Ramon, et al.
Publicado: (2020)

Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)

Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
por: Goldstein, Neil, et al.
Publicado: (2020)

A two-dose heterologous prime-boost vaccine regimen eliciting sustained immune responses to Ebola Zaire could support a preventive strategy for future outbreaks
por: Shukarev, Georgi, et al.
Publicado: (2016)

Immune response of a two-dose heterologous Ebola vaccine regimen: summary of three African clinical trials using a single validated Filovirus Animal Nonclinical Group enzyme-linked immunosorbent assay in a single accredited laboratory
por: McLean, Chelsea, et al.
Publicado: (2023)

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021)

SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COV2.S vaccination predict durable protection in rhesus macaques
por: Roozendaal, Ramon, et al.
Publicado: (2021)

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
por: Bockstal, Viki, et al.
Publicado: (2022)

Impact of Preexisting Anti–Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine( )
por: Le Gars, Mathieu, et al.
Publicado: (2022)

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
por: Afolabi, Muhammed O, et al.
Publicado: (2022)

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
por: Ishola, David, et al.
Publicado: (2022)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination — Response from the Manufacturer
por: Sadoff, Jerald, et al.
Publicado: (2021)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022)

LB7. Ad26.COV2.S-Elicted Neutralizing Activities Against SARS-CoV-2 Variants of Concern in Phase 1/2a and Phase 3 Clinical Trials
por: Le Gars, Mathieu, et al.
Publicado: (2021)

Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation
por: Pasin, Chloé, et al.
Publicado: (2019)

Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019)

Restrained expansion of the recall germinal center response as biomarker of protection for influenza vaccination in mice
por: Kil, Laurens P., et al.
Publicado: (2019)

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years
por: Comeaux, Christy, et al.
Publicado: (2019)

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018)

Correction: A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates
por: Callendret, Benoit, et al.
Publicado: (2018)

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
por: Barry, Houreratou, et al.
Publicado: (2021)

Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials
por: Sadoff, Jerald, et al.
Publicado: (2022)

Accessing Maternal Health Services in Eastern Burma
por: Douoguih, Macaya
Publicado: (2008)

Durable natural killer cell responses after heterologous two-dose Ebola vaccination
por: Wagstaffe, Helen R., et al.
Publicado: (2021)

Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination
por: Wagstaffe, Helen R, et al.
Publicado: (2019)

Ebola Virus Glycoprotein IgG Seroprevalence in Community Previously Affected by Ebola, Sierra Leone
por: Manno, Daniela, et al.
Publicado: (2022)

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
por: Hardt, Karin, et al.
Publicado: (2022)

Ebola virus glycoprotein stimulates IL-18–dependent natural killer cell responses
por: Wagstaffe, Helen R., et al.
Publicado: (2020)

NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022)

Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COV2.S Vaccination
por: Barouch, Dan H., et al.
Publicado: (2021)

Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19
por: Barouch, Dan H., et al.
Publicado: (2021)

Impact of prophylactic vaccination strategies on Ebola virus transmission: A modeling analysis
por: Potluri, Ravi, et al.
Publicado: (2020)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge
por: van der Lubbe, Joan E. M., et al.
Publicado: (2018)

A plain language summary of how well the single-dose Janssen vaccine works and how safe it is
por: Sadoff, J, et al.
Publicado: (2021)

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study
por: Falsey, Ann R, et al.
Publicado: (2021)

Booster with Ad26.COV2.S or Omicron-adapted vaccine enhanced immunity and efficacy against SARS-CoV-2 Omicron in macaques
por: Solforosi, Laura, et al.
Publicado: (2023)

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults
por: DeVincenzo, John, et al.
Publicado: (2019)

1049. Minimal Transient HIV-1 Viremia Following Vaccination Regimens Containing AD26. ZEBOV and MVA-BN-Filo in ART-Suppressed People Living with HIV
por: Custer, Benjamin L, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1obh9j742084nbduef45nekpr5